On June 2, 2025 BioNTech SE’s American depositary receipt staged a dramatic one-day rally, closing up 18.0% at $113.10. The move came on an otherwise modestly positive day for U.S. equities, with the S&P 500 and Dow Jones Industrial Average advancing only fractionally ( MarketWatch ). What made BioNTech’s performance remarkable was not just the magnitude of the gain but also the unusually high trading volume: roughly 5.3 million shares exchanged hands, far above the company’s

French pharmaceutical giant Sanofi on June 2, 2025 announced an agreement to acquire Blueprint Medicines, a U.S.-based biopharma company known for its work on KIT-driven diseases and systemic mastocytosis, in a deal valued at roughly $9.1 billion in cash up front and up to about $9.5 billion including contingent milestone payments ( Reuters ). The transaction—priced at $129 per share in cash plus contractual contingent rights tied to future milestones—represents a bold strate

Bristol Myers Squibb and BioNTech announced a landmark strategic partnership in mid-2025 to co-develop and co-commercialize a next-generation bispecific antibody candidate aimed at multiple solid tumor types ( Reuters ). The headline figure, an agreement that could total roughly $11.1 billion captures attention because it signals a major legacy oncology company doubling down with an mRNA-era innovator on a therapy designed to combine immune activation with vascular targeting